Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors.

International journal of cancer - 20 May 2003

Chen Hui, Isozaki Koji, Kinoshita Kazuo, Ohashi Akiko, Shinomura Yasuhisa, Matsuzawa Yuji, Kitamura Yukihiko, Hirota Seiichi

Abstract excerpt

Mutations of proto-oncogene c-KIT in gastrointestinal stromal tumors (GISTs) are considered to cause a constitutive activation of KIT responsible for their oncogenesis. Imatinib has therapeutic potential for GISTs because of its inhibitory effect on KIT kinase activity. To investigate the effect of Imatinib on various c-KIT mutations found in GISTs, we examined kinase activity of KIT, cell proliferation and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Gastrointestinal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to MAP Kinase Signaling System

Share to Piperazines

Share to Precipitin Tests

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Source

Identifiers

PMID: 12672043
DOI: 10.1002/ijc.11025

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors.PMID 12672043Read ↗

Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.Semantic proximity Read ↗

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.Semantic proximity Read ↗

Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.Semantic proximity Read ↗

Kit as a human oncogenic tyrosine kinase.Semantic proximity Read ↗

Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation.Semantic proximity Read ↗

In vivo effect of imatinib on progression of cecal GIST-like tumors in exon 17-type c-kit knock-in mice.Semantic proximity Read ↗

Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.Semantic proximity Read ↗

BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor.Semantic proximity Read ↗

MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation.Semantic proximity Read ↗

[Oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor].Semantic proximity Read ↗

A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.Semantic proximity Read ↗

Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.